Obesity

By 2035, more than half of the global population is predicted to be overweight or obese, posing substantial challenges for insurers, policymakers, and healthcare providers. Newer obesity medications offer promising weight loss outcomes, having the potential to reduce morbidity and mortality rates. Insurers need to stay ahead of the curve in understanding the impact of newer treatments on insurance portfolios and develop effective strategies for managing obesity-related risks.  

Munich Re's Life Science Report provides a comprehensive guide to assessing both the promises and pitfalls of emerging medical trends and risks, helping life and health insurers to better navigate this environment of changing mortality and morbidity. The report examines the topics of Artificial Intelligence in Healthcare, Improving Cancer Outcomes, Prevention, Obesity and Climate Change.